ReShape Lifesciences® Receives NIH Supplementary Grant with the University of Southern California’s Center for Autonomic Nerve Recording and Stimulation Systems (CARSS) to Further Develop Next-Generation Electrodes for ReShape’s Proprietary Diabetes Bloc-Stim Neuromodulation™ Technology
ReShape Lifesciences (Nasdaq: RSLS) received a $241,000 supplementary grant from the NIH, in collaboration with USC's CARSS, to develop next-generation electrodes for their Diabetes Bloc-Stim Neuromodulation™ (DBSN™) device. The grant will fund studies testing minimally invasive laparoscopic surgical implantation techniques and long-duration safety experiments. The DBSN™ device uses vagus nerve block technology to treat Type 2 diabetes. This fourth NIH grant brings total funding to $1.15 million, supporting the pre-clinical development of the technology that aims to regulate insulin production and manage blood glucose levels. The next-generation electrodes could potentially double nerve contact area while reducing power consumption.
ReShape Lifesciences (Nasdaq: RSLS) ha ricevuto un finanziamento supplementare di $241.000 dal NIH, in collaborazione con il CARSS dell'USC, per sviluppare elettrodi di nuova generazione per il loro dispositivo Diabetes Bloc-Stim Neuromodulation™ (DBSN™). Il finanziamento sosterrà studi che testano tecniche di impianto chirurgico laparoscopico minimamente invasivo e esperimenti di sicurezza a lungo termine. Il dispositivo DBSN™ utilizza la tecnologia di blocco del nervo vago per trattare il diabete di tipo 2. Questo quarto finanziamento NIH porta il totale a $1,15 milioni, supportando lo sviluppo preclinico della tecnologia che mira a regolare la produzione di insulina e gestire i livelli di glucosio nel sangue. Gli elettrodi di nuova generazione potrebbero raddoppiare potenzialmente l'area di contatto con il nervo riducendo al contempo il consumo energetico.
ReShape Lifesciences (Nasdaq: RSLS) recibió una subvención suplementaria de $241,000 del NIH, en colaboración con el CARSS de USC, para desarrollar electrodos de nueva generación para su dispositivo Diabetes Bloc-Stim Neuromodulation™ (DBSN™). La subvención financiará estudios que prueben técnicas de implantación quirúrgica laparoscópica mínimamente invasivas y experimentos de seguridad a largo plazo. El dispositivo DBSN™ utiliza la tecnología de bloqueo del nervio vago para tratar la diabetes tipo 2. Esta cuarta subvención del NIH eleva la financiación total a $1.15 millones, apoyando el desarrollo preclínico de la tecnología que busca regular la producción de insulina y gestionar los niveles de glucosa en sangre. Los electrodos de nueva generación podrían potencialmente duplicar el área de contacto con los nervios mientras reducen el consumo de energía.
ReShape Lifesciences (Nasdaq: RSLS)는 USC의 CARSS와 협력하여 Diabetes Bloc-Stim Neuromodulation™ (DBSN™) 장치의 차세대 전극 개발을 위한 NIH의 $241,000 보조금을 받았습니다. 이 보조금은 최소 침습적인 복강경 수술 이식 기술과 장기 안전 실험을 테스트하는 연구에 자금을 지원할 것입니다. DBSN™ 장치는 제2형 당뇨병 치료를 위해 미주 신경 차단 기술을 사용합니다. 이번 네 번째 NIH 보조금으로 총 자금은 $1.15 백만 달러에 달하며, 인슐린 생산을 조절하고 혈당 수치를 관리하는 기술의 전임상 개발을 지원합니다. 차세대 전극은 신경 접촉 면적을 두 배로 늘리고 전력 소비를 줄일 수 있는 잠재력이 있습니다.
ReShape Lifesciences (Nasdaq: RSLS) a reçu une subvention supplémentaire de 241 000 $ du NIH, en collaboration avec le CARSS de l'USC, pour développer des électrodes de nouvelle génération pour leur appareil Diabetes Bloc-Stim Neuromodulation™ (DBSN™). La subvention financera des études testant des techniques d'implantation chirurgicale laparoscopique mini-invasives et des expériences de sécurité à long terme. L'appareil DBSN™ utilise la technologie de blocage du nerf vague pour traiter le diabète de type 2. Cette quatrième subvention du NIH porte le financement total à 1,15 million $, soutenant le développement préclinique de la technologie visant à réguler la production d'insuline et à gérer les niveaux de glucose dans le sang. Les électrodes de nouvelle génération pourraient potentiellement doubler la surface de contact nerveux tout en réduisant la consommation d'énergie.
ReShape Lifesciences (Nasdaq: RSLS) hat eine zusätzliche Förderung in Höhe von 241.000 $ vom NIH erhalten, in Zusammenarbeit mit dem CARSS der USC, um Elektroden der nächsten Generation für ihr Gerät Diabetes Bloc-Stim Neuromodulation™ (DBSN™) zu entwickeln. Die Förderung wird Studien finanzieren, die minimal-invasive laparoskopische Implantationstechniken und Langzeitsicherheitsexperimente testen. Das DBSN™-Gerät nutzt die Vagusnervblockade-Technologie zur Behandlung von Typ-2-Diabetes. Diese vierte NIH-Förderung erhöht die Gesamtfinanzierung auf 1,15 Millionen $, um die präklinische Entwicklung der Technik zu unterstützen, die darauf abzielt, die Insulinproduktion zu regulieren und den Blutzuckerspiegel zu verwalten. Die Elektroden der nächsten Generation könnten potenziell die Nervenkontaktfläche verdoppeln und gleichzeitig den Energieverbrauch senken.
- Secured $241,000 non-dilutive NIH grant funding
- Total NIH funding reached $1.15 million
- Strong IP portfolio with 74 issued or pending patents
- Successful pre-clinical development completion
- Technology demonstrates potential to reduce medication dependence
- Still in pre-clinical development phase
- Requires further testing and validation
Insights
The
The preclinical data from both Zucker rat and alloxan-treated swine models demonstrates promising glycemic control. The focus on minimally invasive laparoscopic implantation techniques could improve the procedure's safety profile and adoption rate. However, investors should note that significant clinical trials and regulatory approvals are still required before commercialization.
With 74 patents covering vBloc, glucose control and AI applications, the IP portfolio provides reasonable protection for future development. The non-dilutive funding strategy helps preserve shareholder value while advancing R&D.
Approximately
IRVINE, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that the Company was awarded an approximately
“ReShape's DBSN™ device effectively regulates vagal block and stimulation to the liver and pancreas, respectively, resulting in improved blood glucose management. This has been demonstrated through successful glycemic control in a Zucker rat model of Type 2 diabetes and an alloxan treated swine model of Type 2 diabetes, with the support of prior NIH grants,” stated Jonathan Waataja, Ph.D. Director of Research at ReShape Lifesciences®. “This non-dilutive supplemental grant, awarded over the course of one year will fund studies to test the safety and efficacy of a the next-generation electrodes which can potentially double the nerve contact area to increase the effectiveness of delivering DBSN signals while reducing power consumption. We look forward to collaborating with CARSS to further the development of the novel DBSN™ device as a potential treatment for diabetes and hypoglycemia.”
“This fourth grant from the NIH brings our total received awards to
About Diabetes Bloc-Stim Neuromodulation™ Device
The Diabetes Bloc-Stim Neuromodulation™ (DBSN™) system is a novel therapeutic concept that is implanted minimally invasively and delivers bio-electronic neuromodulation of vagus nerve branches that are innervating organs which regulate plasma glucose. The DBSN™ system stimulates vagus celiac fibers of the pancreas to release insulin during stimulation, while blocking the hepatic vagal branch, innervating the liver, to decrease glucose release and decrease insulin resistance following ligation. The DBSN™ system utilizes a proprietary, reversable and adjustable electrical blockade that we believe is key to the future of personalized medicine. We believe the DBSN™ system is superior to both standalone stimulation of the vagus nerve that has shown mixed results, and vagus nerve ligation that has undesirable effects.
About ReShape Lifesciences®
ReShape Lifesciences® is America’s premier weight loss and metabolic health-solutions company, offering an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease. The FDA-approved Lap-Band® and Lap-Band® 2.0 Flex Systems provide minimally invasive, long-term treatment of obesity and are an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. The investigational Diabetes Bloc-Stim Neuromodulation™ (DBSN™) system utilizes a proprietary vagus nerve block and stimulation technology platform for the treatment of Type 2 diabetes and metabolic disorders. The Obalon® balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. For more information, please visit www.reshapelifesciences.com.
As previously announced ReShape has entered into an asset purchase agreement with Biorad Medisys, Pvt. Ltd., pursuant to which ReShape has agreed to sell substantially all of its assets to Biorad (or an affiliate thereof), including ReShape’s Lap-Band® System, Obalon® Gastric Balloon System and the DBSN™ system (but excluding cash). Therefore, at the closing of the transactions contemplated by the asset purchase agreement, the DBSN™ system will be owned by Biorad.
Forward-Looking Safe Harbor Statement
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those discussed due to known and unknown risks, uncertainties, and other factors. These forward-looking statements generally can be identified by the use of words such as "expect," "plan," "anticipate," "could," "may," "intend," "will," "continue," "future," other words of similar meaning and the use of future dates. Forward-looking statements in this press release include statements about our continued development of the DBSN™ system and use of the NIH grant funds. These and additional risks and uncertainties are described more fully in the company's filings with the Securities and Exchange Commission, including those factors identified as "risk factors" in our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. We are providing this information as of the date of this press release and do not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise, except as required by law.
CONTACTS
ReShape Lifesciences Investor Contact:
Paul F. Hickey
President and Chief Executive Officer
949-276-7223
ir@ReShapeLifesci.com
Investor Relations Contact:
Rx Communications Group
Michael Miller
917-633-6086
mmiller@rxir.com
FAQ
What is the value of the NIH grant received by ReShape Lifesciences (RSLS)?
What is the purpose of ReShape Lifesciences' (RSLS) DBSN device?
How many patents does ReShape Lifesciences (RSLS) have for their DBSN technology?